NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $15.86 +1.30 (+8.93%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$14.79▼$15.9750-Day Range$12.67▼$17.5252-Week Range$3.35▼$17.58Volume942,545 shsAverage Volume888,406 shsMarket Capitalization$826.62 millionP/E RatioN/ADividend YieldN/APrice Target$20.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Stoke Therapeutics alerts: Email Address Stoke Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside29.7% Upside$20.57 Price TargetShort InterestBearish19.76% of Shares Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.11Based on 17 Articles This WeekInsider TradingSelling Shares$137,500 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.30) to ($2.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.50 out of 5 starsMedical Sector298th out of 936 stocksPharmaceutical Preparations Industry137th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Stoke Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.76% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 2.8 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.Search Interest10 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows3 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,500.00 in company stock.Percentage Held by Insiders11.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Stoke Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.30) to ($2.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Stoke Therapeutics Stock (NASDAQ:STOK)Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Read More STOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesJuly 4, 2024 | insidertrades.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 10,000 Shares of StockJuly 26 at 5:52 AM | msn.comAmbani Wedding in London: Stoke Park Hotel Issues Statement on Anant-Radhika's Function Rumours, Says 'No Event Booked'July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 26 at 12:52 AM | uk.news.yahoo.comThree lingering questions for Stoke City to solve as plates spin on burning issuesJuly 26 at 12:52 AM | msn.comDwight Gayle among ex-Stoke City trio searching for end to transfer limbo at PFA free agent campJuly 25 at 2:50 PM | msn.comStoke boss delivers firm message on Bae Junho and Wouter Burger amid Tottenham and Feyenoord transfer talkJuly 25 at 2:50 PM | msn.comMissing Buxton teen last seen at Stoke-on-Trent beauty spot days agoJuly 25 at 2:50 PM | uk.news.yahoo.comSchoolgirl, 13, disappears in Stoke-on-Trent three days ago and hasn't been seen sinceJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 2:50 PM | msn.comChange of squad number for Bae Junho as Stoke City leave big vacancyJuly 23 at 9:43 PM | msn.comPete Smith's Stoke City player ratings vs Crewe as Andre Vidigal stakes his claim with braceJuly 23 at 4:42 PM | msn.comStoke City team news vs Crewe Alexandra as duo returnJuly 23 at 4:42 PM | msn.comRecord number of school suspensions in StokeJuly 23 at 4:42 PM | msn.comCrash claims life of driver and puts passenger in Royal StokeJuly 21, 2024 | morningstar.comStoke Therapeutics Inc 0GTJuly 20, 2024 | uk.news.yahoo.comStoke City to open bet365 Stadium doors for training sessionJuly 20, 2024 | msn.com'Noisy' Gibson vows to help Stoke 'do good things'July 20, 2024 | msn.comRecord number of gonorrhoea and syphilis cases in StokeSee More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$20.57 High Stock Price Target$35.00 Low Stock Price Target$13.00 Potential Upside/Downside+32.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,700,000.00 Net MarginsN/A Pretax Margin-1,383.58% Return on Equity-65.47% Return on Assets-46.66% Debt Debt-to-Equity RatioN/A Current Ratio5.43 Quick Ratio5.43 Sales & Book Value Annual Sales$8.78 million Price / Sales91.89 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book4.34Miscellaneous Outstanding Shares52,120,000Free Float46,231,000Market Cap$806.82 million OptionableOptionable Beta0.87 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 75)Ph.D., CEO & Director Comp: $948.9kDr. Adrian R. Krainer Ph.D. (Age 65)Co-Founder & Independent Director Comp: $44kDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Chief Medical Officer Comp: $684.55kMs. Isabel Aznarez Ph.D. (Age 51)Co-Founder & Group VP of Discovery Research Mr. Thomas Edward Leggett (Age 47)Chief Financial Officer Dr. Huw M. Nash Ph.D. (Age 57)COO & Chief Business Officer Comp: $429.67kMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 34)Corporate Secretary & General Counsel Ms. Dawn Kalmar (Age 46)Chief Communications Officer Ms. Joan WoodChief Human Resources OfficerMore ExecutivesKey CompetitorsArcturus TherapeuticsNASDAQ:ARCTHeron TherapeuticsNASDAQ:HRTXRevance TherapeuticsNASDAQ:RVNCMersana TherapeuticsNASDAQ:MRSNShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 25,988 shares on 7/26/2024Ownership: 0.222%Nisa Investment Advisors LLCBought 1,038 shares on 7/20/2024Ownership: 0.006%Assenagon Asset Management S.A.Bought 1,468,202 shares on 7/18/2024Ownership: 2.817%SG Americas Securities LLCBought 58,943 shares on 7/12/2024Ownership: 0.132%Barry TichoSold 10,000 sharesTotal: $137,500.00 ($13.75/share)View All Insider TransactionsView All Institutional Transactions STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK stock has increased by 201.5% and is now trading at $15.86. View the best growth stocks for 2024 here. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings data on Monday, May, 6th. The company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.03. The firm earned $4.22 million during the quarter, compared to the consensus estimate of $3.33 million. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Top institutional investors of Stoke Therapeutics include Assenagon Asset Management S.A. (2.82%), Bank of New York Mellon Corp (0.22%), SG Americas Securities LLC (0.13%) and Nisa Investment Advisors LLC (0.01%). Insiders that own company stock include Skorpios Trust, Stephen J Tulipano, Jonathan Allan, Barry Ticho and Huw M Nash. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL) and Kaleido Biosciences (KLDO). This page (NASDAQ:STOK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
